Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin
about
Potential of RAS inhibition to improve metabolic bone disordersPicomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime RegionThe Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesAliskiren: the first renin inhibitor for clinical treatmentFragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndromeLocal delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.Is there a future for renin inhibitors?The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction.Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations.Role of aliskiren in blood pressure control and renoprotectionEvaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzymeDevelopment and validation of a HPLC-PDA bioanalytical method for the simultaneous estimation of Aliskiren and Amlodipine in human plasma.In silico pharmacology for drug discovery: applications to targets and beyondAliskiren: a renin inhibitor offering a new approach for the treatment of hypertension.The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins.The Renin Report.Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 ratRenin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance.Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat.The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.Aliskiren: clinical experience and future perspectives of renin inhibition.Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression.A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney diseaseOn target to dual block RAS?Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis.Update on newer antihypertensive medicines and interventions.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment.Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations.Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors.New roles for renin and prorenin in heart failure and cardiorenal crosstalk.Renin inhibitors and cardiovascular and renal protection: an endless quest?Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.Structure-based drug screening for G-protein-coupled receptorsInhibition of renin and the (pro)renin receptor system.The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient.In silico analysis and molecular modeling of RNA polymerase, sigma S (RpoS) protein in Pseudomonas aeruginosa PAO1.Renin Inhibition with Aliskiren: A Decade of Clinical Experience.
P2860
Q26866515-9557B526-1B2C-4793-BCBC-1BF747F51EADQ27345457-1DAF22AD-A5D4-40A9-9FBA-9AD8327A6512Q27489856-4A1F3B12-A155-457F-9543-69408168496DQ28272666-05F29286-6943-4CAB-A542-BB8A31F3D422Q33403707-8C2772A8-DCAA-4696-842B-6919C1C82A49Q33840829-D3C677E9-D931-4824-8B99-B4C84EC72A68Q34156850-8B5BCEE7-A377-4739-9204-8766B6FD7F70Q34167168-F9418CD4-1518-4498-8E6E-8A480DB45544Q34355679-F66B7FDB-59B8-4E9F-BBE1-0B193A3880AFQ34481473-0F9C37FB-5054-45C3-9533-0461496B3662Q34906937-97BC4F19-949F-40BB-B6CF-8CC90FF9CC71Q35026735-8610F18A-E34C-4266-BAEE-E8F468A9CFB8Q35112957-CA206C91-5EFB-403D-8C07-0E1A762F84C7Q35188590-2A8B4844-2CC9-4F90-93FB-70CABE8D8652Q35995265-A3B7CDA6-5A54-4CE5-99FC-BA0A4E2ACD12Q36600306-D426F344-EF67-42AE-9757-8036F2CEF8F9Q36604792-8A08A34A-F3D9-44C9-A6A9-0F765DF1EF75Q36755471-BA6B90A6-B519-4DFE-8A1D-60CEAC539F89Q36805458-31F38E0A-CC53-49AF-A587-13C09E6E10D7Q36857263-86F1ACCD-5A59-4C9F-8066-0DEE85AAFB72Q36976385-90AEF686-B46F-4719-9BE0-79DDB62BFB6EQ37019887-56E43DDB-EB88-432F-AE5E-B26DC1841B3DQ37111865-508A0776-C8CE-411F-AAF0-C203DEE074B7Q37210815-074DE57A-300E-46A2-96E0-3523B7B19B2EQ37322017-99AAA375-A774-4E6C-83ED-007662452B36Q37368669-CEAF6280-0FC6-448B-A785-7AA2913F21CCQ37620992-84DA0E02-EA29-4892-8ACF-0FEED940EAD1Q37753547-C4FFE6F6-A9DC-4BB3-92C0-18894020BF83Q37781702-6A9CE9F7-8CA4-400F-8C99-737677F8198FQ37812140-81BD0BA2-1560-4E47-88C1-34E101F7B255Q37862922-BB5FFFFD-3400-4868-84DB-7DF0C67DF1A5Q37866692-136F8D44-75D2-4A1E-9935-709A9D4283C2Q37893014-CDB61F9D-E71E-48FF-B7D0-D40ADB0561ADQ37990796-01E974EF-8E64-4107-9C75-6EB707916705Q37993917-A6ED15F7-24A7-4E8B-950A-1A081D427013Q38002626-590C51BF-C2D3-49F5-968E-7CEDBE401D33Q38024862-2F1375EA-AA40-463C-8BC4-7B7C4550590DQ38154260-87A6A525-5572-405C-9A2C-94A44EEFC280Q38534094-0D7FF47F-2E58-4123-BEE2-5E5C50D33812Q38672900-36265C99-D0C1-4375-A758-62904571E0B8
P2860
Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Structure-based drug design: t ...... tive inhibitors of human renin
@ast
Structure-based drug design: t ...... tive inhibitors of human renin
@en
Structure-based drug design: t ...... tive inhibitors of human renin
@nl
type
label
Structure-based drug design: t ...... tive inhibitors of human renin
@ast
Structure-based drug design: t ...... tive inhibitors of human renin
@en
Structure-based drug design: t ...... tive inhibitors of human renin
@nl
prefLabel
Structure-based drug design: t ...... tive inhibitors of human renin
@ast
Structure-based drug design: t ...... tive inhibitors of human renin
@en
Structure-based drug design: t ...... tive inhibitors of human renin
@nl
P2093
P1476
Structure-based drug design: t ...... tive inhibitors of human renin
@en
P2093
M G Grütter
P304
P356
10.1016/S1074-5521(00)00134-4
P407
P577
2000-07-01T00:00:00Z